Inventor · disambiguated record
Bingshi Guo
Also filed as: GUO BINGSHI
17 granted patents·13 pending applications·55 citations·filing 2017–2023
91Inventor score
Top patents by PatentIndex Score
30 records- 0195US10584169B2Anti-CD73 antibodies and uses thereofI MAB·Filed 2018·Granted Mar 10, 2020·11 cites·14 claims
- 0293US10059769B2Anti-PD-L1 antibodies and uses thereofI MAB·Filed 2017·Granted Aug 28, 2018·15 cites·11 claims
- 0392US10208119B2Anti-PD-L1 antibodies and uses thereofI MAB·Filed 2018·Granted Feb 19, 2019·11 cites·18 claims
- 0488US11034771B2Anti-CD73 anti-PD-L1 bispecific antibodiesI MAB BIOPHARMA US LTD·Filed 2019·Granted Jun 15, 2021·9 cites·23 claims
- 0584US10723799B2Anti-PD-L1 antibodies and uses thereofI MAB·Filed 2018·Granted Jul 28, 2020·1 cites·18 claims
- 0682US11261259B2Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereofI MAB BIOPHARMA US LTD·Filed 2020·Granted Mar 1, 2022·1 cites·19 claims
- 0781US11926662B2Anti-GM-CSF antibodies and uses thereofI MAB BIOPHARMA HANGZHOU CO LTD·Filed 2020·Granted Mar 12, 2024·1 cites·8 claims
- 0881US10577421B2Anti-LAG-3 antibodies and uses thereofI MAB·Filed 2018·Granted Mar 3, 2020·3 cites·11 claims
- 0979US11220546B2Anti-PD-L1 antibodies and uses thereofI MAB·Filed 2019·Granted Jan 11, 2022·1 cites·19 claims
- 1073US11401331B2Anti-PD-L1 antibody and IL-7 fusionsI MAB BIOPHARMA US LTD·Filed 2019·Granted Aug 2, 2022·1 cites·6 claims
- 1172US10647767B2Anti-GM-CSF antibodies and uses thereofI MAB BIOPHARMA CO LTD·Filed 2017·Granted May 12, 2020·1 cites·22 claims
- 1267US11613577B2Anti-CD73 antibodies and uses thereofI MAB BIOPHARMA US LTD·Filed 2020·Granted Mar 28, 2023·0 cites·8 claims
- 1367US2020317789A1Anti-pd-l1 antibodies and uses thereofI MAB BIOPHARMA US LTD·Filed 2020·Application pending·0 cites
- 1466US2022119531A1Anti-pd-l1 antibodies and uses thereofI MAB BIOPHARMA US LTD·Filed 2021·Application pending·0 cites
- 1565US12091467B2CD47 monoclonal antibodies and uses thereofI MAB BIOPHARMA US LTD·Filed 2020·Granted Sep 17, 2024·0 cites·4 claims
- 1665US11414485B2Anti-LAG-3 antibodies and uses thereofI MAB BIOPHARMA US LTD·Filed 2019·Granted Aug 16, 2022·0 cites·14 claims
- 1759US2025074995A1Multispecific constructs and uses thereofI MAB BIOPHARMA CO LTD·Filed 2023·Application pending·0 cites
- 1857US10889641B2Anti-GM-CSF antibodies and uses thereofI MAB BIOPHARMA CO LTD·Filed 2018·Granted Jan 12, 2021·0 cites·14 claims
- 1956US2020407441A1Fusion Proteins Containing CD48 Antibodies and CytokinesI MAB BIOPHARMA US LTD·Filed 2019·Application pending·0 cites
- 2056US2020140565A1Novel cd47 monoclonal antibodies and uses thereofI MAB·Filed 2017·Application pending·0 cites
- 2155US2021095019A1Fusion Proteins Containing CD47 Antibodies and CytokinesI MAB·Filed 2018·Application pending·0 cites
- 2255US2023393144A1Methods for mitigating interference by therapeutic anti-cd47 antibodies in pre-transfusion assaysI MAB BIOPHARMA US LTD·Filed 2021·Application pending·0 cites
- 2354US2023399400A1Novel anti-cd47 antibodies and uses thereofI MAB BIOPHARMA CO LTD·Filed 2021·Application pending·0 cites
- 2454US2023174649A1Pharmaceutical compositions containing anti-cd47 antibodiesI MAB BIOPHARMA US LTD·Filed 2021·Application pending·0 cites
- 2552US2024209093A1Single domain pd-l1 antibodiesI MAB BIOPHARMA CO LTD·Filed 2022·Application pending·0 cites
- 2651US11208486B2Human PD-L1 antibodiesI MAB BIOPHARMA US LTD·Filed 2020·Granted Dec 28, 2021·0 cites·18 claims
- 2751US10973853B2Antibodies to T cell immunoreceptor with IG and ITIM domains (TIGIT) and uses thereofI MAB BIOPHARMA US LTD·Filed 2019·Granted Apr 13, 2021·0 cites·7 claims
- 2850US2022112258A1Bifunctional molecules with il-7 activityI MAB BIOPHARMA US LTD·Filed 2020·Application pending·0 cites
- 2949US2021269522A1Novel CD47 Antibodies and Methods of Using SameI MAB BIOPHARMA US LTD·Filed 2019·Application pending·0 cites
- 3046US2019389972A1Modified ck and ch1 domainsI MAB·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Bingshi Guo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →